In the last trading session, 1.16 million Day One Biopharmaceuticals Inc (NASDAQ:DAWN) shares changed hands as the company’s beta touched -1.45. With the company’s per share price at $17.17 changed hands at -$0.4 or -2.28% during last session, the market valuation stood at $1.50B. DAWN’s last price was a discount, traded about -5.24% off its 52-week high of $18.07. The share price had its 52-week low at $9.67, which suggests the last value was 43.68% up since then. When we look at Day One Biopharmaceuticals Inc’s average trading volume, we note the 3-month average coming to 1.03 million.
Day One Biopharmaceuticals Inc (NASDAQ:DAWN) trade information
Instantly DAWN was in red as seen at the end of in last trading. With action 15.08%, the performance over the past five days has been green. The drop to weekly highs of 18.07 subtracted -2.28% to the stock’s daily price. The company’s shares are showing year-to-date upside of 17.60%, with the 5-day performance at 15.08% in the green. However, in the 30-day time frame, Day One Biopharmaceuticals Inc (NASDAQ:DAWN) is 20.92% up.
Day One Biopharmaceuticals Inc (DAWN) estimates and forecasts
Data shows that the Day One Biopharmaceuticals Inc share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 45.02% over the past 6 months, a -12.66% in annual growth rate that is considerably lower than the industry average of 13.00%. Moreover, analysts have looked to lower expectations by upgrading its fiscal year 2024 revenue estimates. The rating firms predict current quarter revenue for Day One Biopharmaceuticals Inc will fall -11.90%, while the growth in revenue is estimated to hit -9.80% for the next quarter.
Consensus estimates given by 6 financial analysts project the company’s revenue in the current quarter to hit an average of -$. 8 analysts are of the opinion that Day One Biopharmaceuticals Inc’s revenue for the quarter ending Jun 2024 will be $890k. The company’s revenue for the corresponding quarters a year ago was -$.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -84.59%. The 2024 estimates are for Day One Biopharmaceuticals Inc earnings to decrease by -11.28%.
DAWN Dividends
Day One Biopharmaceuticals Inc is expected to release its next quarterly earnings report in June.
